Skip to Content

Zytiga (abiraterone) Disease Interactions

There are 2 disease interactions with Zytiga (abiraterone):


Abiraterone (Includes Zytiga) ↔ hepatic impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Postmarketing studies have associated the use of abiraterone with severe hepatic toxicity, including fulminant hepatitis, acute liver failure and deaths. Serum transaminases and bilirubin levels should be measured before starting treatment and every 2 weeks for the first three months of treatment and then monthly thereafter. Any liver test elevations should prompt more frequently monitoring. Treatment should be discontinued permanently in patients with concurrent elevations of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN. In patients with baseline moderate hepatic impairment (Child-Pugh Class B), the recommended dose should be reduced to 250 mg once daily. Abiraterone should not be used in patients with severe hepatic impairment (Child-Pugh Class C).


Abiraterone (Includes Zytiga) ↔ CVD

Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease, Arrhythmias, History - Myocardial Infarction, Hypokalemia, Fluid Retention

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

Zytiga (abiraterone) drug interactions

There are 667 drug interactions with Zytiga (abiraterone)

Zytiga (abiraterone) alcohol/food interactions

There is 1 alcohol/food interaction with Zytiga (abiraterone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.